key: cord-0991423-awsxy2qo authors: Nomura, Shosaku; Taniura, Takehito; Ito, Tomoki title: Extracellular Vesicle-Related Thrombosis in Viral Infection date: 2020-08-26 journal: Int J Gen Med DOI: 10.2147/ijgm.s265865 sha: 2ec2aa51814195a8d894c05b5e0ea4ebfdedf487 doc_id: 991423 cord_uid: awsxy2qo Although the outcomes of viral infectious diseases are remarkably varied, most infections cause acute diseases after a short period. Novel coronavirus disease 2019, which recently spread worldwide, is no exception. Extracellular vesicles (EVs) are small circulating membrane-enclosed entities shed from the cell surface in response to cell activation or apoptosis. EVs transport various kinds of bioactive molecules between cells, including functional RNAs, such as viral RNAs and proteins. Therefore, when EVs are at high levels, changes in cell activation, inflammation, angioplasty and transportation suggest that EVs are associated with various diseases. Clinical research on EVs includes studies on the coagulatory system. In particular, abnormal enhancement of the coagulatory system through EVs can cause thrombosis. In this review, we address the functions of EVs, thrombosis, and their involvement in viral infection. Most viruses are small sized (typically 0.02 to 0.3 μm), unlike large and megaviruses whose maximum lengths can reach 1 μm in length at the maximum. [1] [2] [3] The reproduction of a virus depends on bacterial, plant, and animal cells including those in humans. 4 Viruses are classified according to genomic properties and structures as well as their reproduction method, and not according to the disease that each virus causes. 5 Replication in DNA viruses typically occurs in the nucleus of the host cell, whereas RNA virus replication typically occurs in the cytoplasm. 5, 6 There are exceptions, however. For example, H1N1 (an RNA virus) cannot reproduce in the host's cytoplasm, whereas vaccinia (a DNA virus) does not need the nucleus to reproduce. After reproduction of a complete virus particle, the host cell typically perishes and the virus is released to infect other host cells. [4] [5] [6] Although the outcomes of viral infectious diseases are remarkably varied, most infections cause acute disease after a short period. 7 Novel coronavirus disease 2019 (COVID- 19) , which recently spread worldwide, is no exception. 8, 9 Extracellular vesicles (EVs) are small circulating membrane-enclosed entities shed from cell surface in response to cell activation or apoptosis. 10 Although detailed understanding of EVs is lacking, information about EVs has been accumulating. [11] [12] [13] EVs measure 0.01-4 μm and are generated by various processes. 11, 12 EVs transport various types of molecules between cells, such as viral RNAs and proteins. [14] [15] [16] Therefore, when EVs are at high levels, cell activation, inflammation, angioplasty and states involving transportation occur, indicating the association of EVs with various diseases. 11, 14, [17] [18] [19] Clinical research of EVs includes studies on the coagulatory system. In particular, abnormal enhancement of the coagulatory system by EVs can cause thrombosis and disseminated intravascular coagulation (DIC). Such an abnormality after a viral infectious disease can become a significant clinical problem. In this review, we address the functions of EVs, thrombosis, and their involvement in viral infection. EVs are classified into three groups by size, namely exosomes, microvesicles (MVs), and apoptotic bodies (ABs) ( Table 1) . 11 Exosomes are EVs with diameters of 30-200 nm, and these membrane-bound vesicles can be precipitated by ultracentrifugation at 100,000×g. 11, 12, 15, 20 Most exosomes carry specific proteins reflecting the characteristics of the origin cell. [21] [22] [23] They form through multi-vesicular bodies (MVBs) that fuse with the cell membrane for release. 15, 24, 25 Exosomes are released from a cell via a mechanism of endosomal complexes required for transport ( Figure 1 ). 26 MVs are EVs of 10-1000 nm in size. 11 MVs are also called microparticles (MPs). 10, 11, 27 The differences between MVs and exosomes other than their size are the processes of formation and secretion. 15, 28 MVs are generated by the surface of the cell breaking off, which is controlled by cell activation. 29 The plasma membrane includes several kinds of phospholipids. 11, 30 The internal leaflet contains aminophosphatides (eg, phosphatidylserine:PS) for a negative charge. 30 MV biogenesis, which occurs via blebbing, is a fragmentation phenomenon whereby nascent MVs are released into the extracellular space via pinching off from the plasma membrane. 31, 32 MVs contain distinct protein and lipid components from the plasma membrane. 32 During cell activation, the charge of the leaflet changes the structure of the normal lipid layer, and PS is exposed to MV ( Figure 1 ). 33 This leads to procoagulant activity in the MVs. 34 EVs generated by apoptosis are called apoptotic bodies (ABs). 11, 35, 36 During its final phase of apoptotic death, the cell divides into several Ab, 32 the size of which are 1000-3000 nm. 37, 38 Similar to MVs, ABs are formed by PS moving to the cell surface. [33] [34] [35] ABs may contain a wide variety of cellular components, such as micronuclei, chromatin remnants, cytosol portions, degraded proteins, DNA fragments, and even intact organelles. 32 The main difference between ABs and MVs is the existence of materials derived from the nucleus such as histones and DNA fragments ( Figure 1 ). 39, 40 EVs can carry activated coagulation factors, by expressing phosphatides on their surface. 11 Therefore, it is thought that the existence of EVs is related to several diseases, indicating a coagulatory promotion tendency. 11, 27 Because EVs promote intravascular coagulation to support thrombin generation, they may be linked with coagulation abnormalities. 27 The procoagulant activity observed on platelet-derived EV surfaces is 50 to 100-fold higher than that observed on activated platelets. 41 This suggests that the coagulatory promotion by EVs is an important defense mechanism for bleeding risk. 11 EVs also carry tissue factor (TF) that is important to activate the coagulation system. 42 The main characteristics of atherosclerosis are the adhesion of monocytes to the endothelium and movement of monocytes into the subendothelium. 27 When a monocyte is activated by platelet-derived EVs and adheres to the endothelium, several inflammatory cytokines are generated. 43 Furthermore, stimulation or activation of the endothelium by EVs increases the expression of adhesion molecules on the endothelial surface. 43, 44 Atherosclerotic lesions can develop and progress in severity via the apoptosis of endothelial cells, a process induced by a substantial number of EV-dependent coagulatory factors. 11, 27, 45 EV appear to constitute a new system of cell-cell communication. 16, 46, 47 EVs have various important functions such as coagulatory promotion, immunosuppression, and angioplasty. 48, 49 EVs may be the most suitable mechanism through which cells communicate with others. 15, 48 For example, EVs produced by one kind of cell stimulate another specific cell. 50, 51 EVs carry tetraspanin protein and may employ a mechanism that can return in a specific organization. 52, 53 Another mechanism involves fusion with the cell membrane, which results in the transfer of mRNA, micro(mi)RNA, proteins, and signaling molecules by EVs. 54, 55 The existence of miRNAs has been found in EVs released with biological fluid of patients with various viral infectious diseases. 13,56-58 EVs might play a crucial role in dissemination of pathogens as well as host-derived molecules during infection. 58 Therefore, EVs may be strongly involved in progression of the post-viral condition and the origin of complications. 59 Ebola, H1N1 influenza, cytomegalovirus, chickenpoxherpes zoster, hepatitis C virus, human immunodeficiency virus (HIV), coxsackie virus B3, herpes simplex virus-1, dengue, and Junin virus are accompanied by thrombotic complications and bleeding. [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] There are at least two major factors underlying the onset of thrombosis that are associated with these viral infections ( Figure 2 ). 72, 73 One factor influencing the blood vessel system is the viruses themselves, because they can influence monocytes, neutrophils and the blood vessel endothelium and also induce the expression of TF. 74 Some viruses can also directly influence platelets and enhance PS expression during their infections. [75] [76] [77] Plasma from influenza patients may also contain MVs with TF activity. 78 This leads to strong thrombosis onset, by enhancing the activity of the exogenous coagulatory system. The second mechanism influences the immune system. The viral infection influences the immune system, and inflammation with the cell which immunity decreased spreads, and an imbalance between coagulation and anti-coagulation occurs. 79 This mechanism is related to interactions between the virus and Tolllike receptors (TLRs). 70, 79 Ebola Virus (EBOV) EBOV is a negative-sense RNA virus that causes a severe disease characterized by high fever, diarrhea, and unexpected onset of vomiting. 80 Additionally, this virus causes a serious procoagulatory abnormality with liver damage. 80 EBOV infection induces TF expression in infected cells and serum D-dimer rises, finally causing DIC. 81 EBOV disrupts the functions of dendritic cells coordinating a T cell increase. 82, 83 Therefore, it is thought that EBOV infectious disease develops a thrombotic tendency by failure of the immune system and enhancement of coagulation. 70, 84 Influenza A Virus (IAV) Influenza A virus (IAV) is a negative-sense RNA virus that commonly causes death. 85 Cardiovascular system disorders, such as acute myocardial infarction, deep vein thrombosis, and pulmonary embolism, are observed. [86] [87] [88] [89] [90] Disorder of the blood vessel wall barrier by IAV may contribute to the development of pulmonary damage in patients with influenza. 91,92 H5N1-infected chickens show microthrombosis and thrombocytopenia. 93 IAV infectious disease causes a high level of plasma von Willebrand factor (vWF) and a decrease of a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS13), which may result in clot-related microangiopathy. 94, 95 Therefore, IAV infectious disease is thought to cause immunity and aggravation of the wall system, which results in inflammatory induction and coagulatory enhancement. Human immunodeficiency virus (HIV) is a positive-sense single-stranded enveloped RNA virus of the Retroviridae family. 96 One cause of death in HIV-infected patients is cardiovascular disease (CVD), and functional disorder in the blood walls caused by HIV reproduction is a considerable determinant of it. [96] [97] [98] Additionally, the immune reaction and inflammation caused by HIV infection may be cardiovascular risks. 99, 100 The death rate is strongly related to interleukin (IL)-6, high sensitivity C-reactive protein (hsCRP), and D-dimer. In particular, IL-6 and hsCRP are related to the development of acquired immunodeficiency syndrome. 101, 102 Funderburg et al 103, 104 reported that TF expression on the surface of monocytes increases in HIV patients. Additionally, Harley et al 105 reported that T-cell kinetics and activity of the thrombin-PAR1 signaling axis are increased by proinflammatory cytokines during HIV infection and contribute to adaptive immunoreactions. Furthermore, young patients with HIV infection have a high level of vWF and a low level of ADAMTS13, which are related to stroke. 106 Therefore, HIV infection has a thrombotic risk through various mechanisms. 107,108 Hepatitis C virus (HCV) is a positive-sense, singlestranded RNA virus of the Flaviviridae family. HCV infection carry the risk of thrombosis, which increases with expression of TF, fibrinolysis interference, and increased platelet aggregation and activation. 109 HCV viral RNA activates TLR-3 in endothelial cells (ECs), leading to inflammation and expression of tumor necrosis factor (TNF)-α. 110 Damaged ECs can affect immune cells through CXCL12 chemokine expression. 111 Through these mechanisms, increased TNF-α induces expression of TF and downregulation of thrombomodulin (TM). 112 Hodowanec et al 113 confirmed that elevation of TF expression and enhancement of coagulatory activity increase in some chronic HCV patients. Similarly, during chronic HCV infectious disease, wall functional disorder caused by plasma vWF levels increases. 114 Coxsackievirus (CoxV) is negative-sense RNA virus of the Picornaviridae family. 70 It is accompanied by a considerable risk of thromboembolism caused by myocarditis. 115 Additionally, myocarditis coagulopathy and hepatic necrosis occur, and ventricular clot formation increases significantly because of platelet activation. 116 Herpes simplex virus (HSV) is double-stranded, linear DNA genome virus of the herpesvirus family. 70 Infection of blood vessel ECs by HSV increases TF activity and reduces TM expression. 69, 117 Sutherland et al 118 reported that HSV type 1 (HSV-1) is a cofactor for PAR-1 that induces TF and glycoprotein C, causing thrombin production. HSV-1 and HSV-2 move FX to the cell surface via internal mechanism phosphatides. [117] [118] [119] It is thought that these viruses drive thrombin generation on the cell surface via this mechanism. 117 Epstein-Barr virus (EBV) belongs to the herpesvirus family and has double-stranded DNA. Its name was changed to human herpesvirus type 4 (HHV-4), but the former name is still widely used. 70 EBV triggers autoantibodyproducing autoimmunity in response to various autoimmune diseases. 120 Patients with EBV experience portal vein thrombosis caused by hypercoagulable syndrome. 121 Cytomegalovirus (CMV) has double-stranded DNA with the generic name of herpesvirus characterized by forming a characteristic inclusion body of the observable "eyes of the owl" state in the nucleus of the host cell under an optical microscope. CMV transforms monocytes and induces production of inflammatory cytokines. Therefore, the incidence of thrombosis in patients with acute CMV infection is common. 121, 122 Corona Virus (CoV) Corona virus (CoV) causes disease in mammals and birds, and has a single strand plus chain RNA genome. 123 In 2003, a CoV epidemic caused by severe acute respiratory syndrome CoV (SARS-CoV-1) emerged in China. 124 SARS-CoV-1 was associated with severe thrombotic complications. 124 Several SARS-CoV-1 cases exhibited pulmonary embolism and deep vein thrombosis. 125 The characteristics of SARS-CoV-1 are a prolonged prothrombin time, prolonged activated partial thromboplastin time, elevated D-dimer, and worsening thrombocytopenia. 126 These findings are consistent with DIC. Furthermore, interestingly, thrombopoietin levels increase in SARS-CoV-1 patients at the convalescent phase compared with normal controls. 127 These findings have also been reported in patients with septic DIC. 128 Another CoV infection was reported in 2012. 129 This CoV was responsible for "Middle East respiratory syndrome" (MERS-CoV). 129 MARS-CoV is similar to SARS-CoV-1 and associated with thrombotic complications. Specifically, DIC is one of the major complications reported in fatal MERS-CoV cases. 130 In 2019, another CoV caused a global pandemic. CoV disease 2019 (COVID-19) is a novel CoV strain disease. 8, 9 COVID-19 patients suffer from severe respiratory or systemic manifestations. Therefore, COVID-19 is also called SARS-CoV-2. 131 Thrombotic complications also emerge in patients with COVID-19. 132-135 COVID-19 patients have elevated D-dimer levels, prolonged prothrombin times, and thrombocytopenia similar to DIC. 132, [136] [137] [138] Both elevated D-dimer levels and thrombocytopenia can be explained by excessive activation of platelets and the coagulation cascade. In contrast, phagocytosis or direct viral targeting by the immune system can also cause these abnormal clinical findings. Thus, viral infections elicit systemic inflammatory immune responses resulting in imbalanced coagulation. 70 EVs from a virally infected cell include not only the virus, but also information on the host. 139 Therefore, EVs are involved in interactions between a virus and various cells of the host. As we have mentioned, the function and role of EVs are varied. 15, 27, 46, 47 Most importantly, EVs that participate in postviral coagulatory abnormalities may be MVs (or MPs), because it appears that most characteristic functions of MVs promote coagulation depending on TF (Figure 2 ). In addition, MVs can substantially increase procoagulant activity on platelet surfaces, thereby contributing to coagulant abnormality during viral infection. 11, 41 In contrast, exosomes contain many functional features, one of which concerns the immune system ( Figure 2 ). 56, [139] [140] [141] [142] For example, lymphatic exosomes promote dendritic cell migration along guidance cues, thereby regulating the immune system. 142 Therefore, it is possible that exosomes do not influence the coagulatory system. EVs are involved in some aspects of viral infectious disease. 143 After infection, for example, EBOV packages the protein moiety characteristic of this virus in EVs. Apoptosis of immune cells in the host is guided by inflammatory cytokines. 144 This drives failure of the homeostasis mechanism in blood vessels, leading to coagulatory abnormalities such as vein clots and DIC. Airway epithelial cells release EVs that neutralize human influenza virus. 145 This mechanism of EVs might play an important role in defense against respiratory viruses. 146 EVs after HIV infection have a significant influence on the immune system. [147] [148] [149] CMVrelated EVs are useful to reinforce infectivity of CMV. 143, 150 Human CMV infection is controlled by T cell-mediated immunity and CMV infects ECs. 151, 152 One of the functions of EC-derived EVs after CMV infection might be contributing to innate surveillance. 151 One role played by post-viral EVs exosomes is their participation in maintaining the pathological state and promoting the spread of viral infection. The main roles of MVs and MPs appear to be in coagulation abnormality. 59, [153] [154] [155] [156] [157] [158] [159] [160] [161] Regarding COVID-19, reports involving EVs are still rare. [162] [163] [164] [165] However, a similar role of exosomes and MVs is assumed in COVID-19 as other virus infectious diseases. [166] [167] [168] [169] [170] In particular, concerning thrombosis, there is no doubt that COVID-19 causes more symptoms in comparison with the past virus infectious disease. 171 Accumulation of important reports of EVs in conjunction with COVID-19 is expected in the future. We have addressed the functions of EVs in thrombosis, and their involvement in viral infections. Clinical research on EVs should include studies on the coagulatory system. In particular, abnormal enhancement of the coagulatory system by EVs can cause thrombosis and DIC (Figure 2 ). There are reports about EVs in some virus infectious diseases. Apoptosis of immune cells in the host is guided by inflammatory cytokines. As a role of post-viral EVs, exosomes participate in pathological maintenance and infection spreading. The main roles of MVs appear to be in coagulation abnormalities. Although many viral infections involve EVs, the role of EVs in COVID-19 is unclear. Nevertheless, thrombosis is a major problem that affects the prognosis of COVID-19 patients. Accumulation of important reports of EVs in conjunction with COVID-19 is expected in the future. A giant virus in amoebae Evolutionary genomics of nucleo -cytoplasmic large DNA viruses Evolution of the large nucleocytoplasmic DNA viruses of eukaryotes and convergent origins of viral gigantism Common, emerging, vector-bone and infrequent abortgenic virus infections of cattle Virus population dynamics during infection RNA epitranscriptomics: regulation of infection of RNA and DNA viruses by N 6 -methyladenosine (M 6 A) Virus taxonomy -1997 Emerging coronaviruses: genome structure, replication, and pathogenesis Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Function and role of microparticles in various clinical settings Extracellular vesicles and blood diseases Extracellular vesicles: exosomes, microvesicles, and friends Focus on extracellular vesicles: new frontiers of cell-to-cell communication in cancer Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Membrane vesicles as conveyors of immune responses Extracellular vesicles and viruses: are they close relatives? A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles Inflammaging and frailty status do not result in an increased extracellular vesicle concentration in circulation Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes Exosomes: extracellular organelles important in intercellular communication Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Syndecan-synternin-ALIX regulates the biogenesis of exosomes Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles Microparticle and atherothrombotic diseases Methodology for isolation, identification and characterization of microvesicles in peripheral blood Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence Leukocyte-derived microparticles in vascular homeostasis Biology and biogenesis of shed microvesicles Apoptotic bodies: particular extracellular vesicles involved in intercellular communication The distribution and function of phosphatidylserine in cellular membranes The role of platelets in atherothrombosis Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro Proteomic characterization of thymocyte-derived microvesicles and apoptotic bodies in BALB/ C mice Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent andindependent mechanisms High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells Modulation of monocyte-endothelial cell interactions by platelet microparticles Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles Biological properties of extracellular vesicles and their physiological functions Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells Extracellular vesicles: structure, function, and potential clinical uses in renal diseases Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs ExoCarta: a compendium of exosomal proteins and RNA Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy Mechanisms of RNA loading into exosomes Trash or treasure: extracellular microRNAs and cell-tocell communication Exosomes and other extracellular vesicles in host-pathogen interactions Exosome biogenesis, regulation, and function in viral infection Hemorrhagic varicella: a case report and review of the complications of varicella in children Viral infections and antiphospholipid antibodies Exotic emerging viral diseases: progress and challenges Effects of human cytomegalovirus infection on the coagulation system Hepatitis C virus infection associated with an increased risk of deep vein thrombosis: a population-based cohort study Pandemic H1N1 influenza infection and vascular thrombosis Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection Human immunodeficiency virus infection and risk of venous thromboembolism Intracardiac thrombus in murine Coxsackievirus B3 myocarditis Virus-specific IgA in serum, saliva, and tears of children with measles Glycoprotein C of herpes simplex virus type 1 is essential for the virus to evade antibody-independent complement-mediated virus inactivation and lysis of virus-infected cells Herpes simplex virus type I does not require productive infection to induce tissue factor in human umbilical vein endothelial cells Procoagulant activity during viral infections Viral infection related venous thromboembolism: potential mechanism and therapeutic targets Review: infectious diseases and coagulation disorders Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3 The role of platelet in mediating a response to human influenza infection Microvesicle tissue factor activity and interleukin-8 levels are associated with mortality in patients with influenza A/H1N1 infection Crosstalk between inflammation and coagulation: the lessons of sepsis Human asymptomatic Ebola infection and strong inflammatory response How Ebola and Marburg viruses battle the immune system Characterization of host immune responses in Ebola virus infections Pathogenesis of filoviral haemorrhagic fevers The coagulation system in host defense Influenza virus and endothelial cells: a species specific relationship Acute myocardial infarction and influenza: a meta-analysis of case-control studies Role of acute infection in triggering acute coronary syndromes Acute cardiac injury events